Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A pragmatic adaptation of the RANO clinical risk score for IDH-Wildtype glioblastoma in the absence of MGMT promoter methylation testing.

Future oncology (London, England) - 1 Aug 2026

Eroğlu İmdat, Koçoğlu Sıla Soylu, Merovci Eron, Savaş Gözde, Gürler Fatih, Sutcuoglu Osman, Coskun Ugur, Uner Aytug, Ucar Murat, Karaarslan Burak, Özet Ahmet, Özdemir Nuriye, Yazıcı Ozan

Abstract excerpt

BACKGROUND: The novel RANO risk score provides prognostic stratification for patients with IDH-wildtype glioblastoma(GBM) and includes age, Karnofsky Performance Scale(KPS), RANO resection class(RRC), and MGMT promoter methylation(MGMTm). However, MGMTm testing is unavailable in many countries. We aimed to explore the prognostic performance of a RANO-adapted clinical score excluding MGMTm. METHODS: We applied the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to DNA Methylation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to DNA Modification Methylases

Share to DNA Repair Enzymes

Share to Glioblastoma

Share to Isocitrate Dehydrogenase

Share to Progression-Free Survival

Share to Tumor Suppressor Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 42550675
DOI: 10.1080/14796694.2026.2713370
PMCID: PMC13540190

Genes

MGMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A pragmatic adaptation of the RANO clinical risk score for IDH-Wildtype glioblastoma in the absence of MGMT promoter methylation testing.PMID 42550675Read ↗

Development and external validation of a clinical prediction model for survival in patients with IDH wild-type glioblastomaSemantic proximity Read ↗

An independently validated nomogram for isocitrate dehydrogenase-wild-type glioblastoma patient survivalSemantic proximity Read ↗

Surgery for Glioblastoma in Light of Molecular Markers: Impact of Resection and MGMT Promoter Methylation in Newly Diagnosed IDH-1 Wild-Type GlioblastomasSemantic proximity Read ↗

No benefit from TMZ treatment in glioblastoma with truly unmethylated MGMT promoter: Reanalysis of the CE.6 and the pooled Nordic/NOA-08 trials in elderly glioblastoma patientsSemantic proximity Read ↗

The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized MRI-derived and clinical features, predict adult primary glioblastoma survival.Semantic proximity Read ↗

Overview of prognostic factors in adult glioma; a 10-year experience at a single institutionSemantic proximity Read ↗

A prognostic model of newly diagnosed glioblastoma based on clinical characteristicsSemantic proximity Read ↗

Clinical value of the MGMT promoter methylation score in IDHmt low-grade glioma for predicting benefit from temozolomide treatmentSemantic proximity Read ↗

Molecular Profile as an Outcome Predictor in Glioblastoma along with MRI Features and Surgical Resection: A Scoping Review.Semantic proximity Read ↗

Differential Predictors and Clinical Implications Associated With Long-Term Survivors in IDH Wildtype and Mutant GlioblastomaSemantic proximity Read ↗

IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival.Semantic proximity Read ↗

Molecularly diagnosed glioblastoma: clinical presentation and outcomes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.